Activity of short lipopeptides and conventional antimicrobials against planktonic cells and biofilms formed by clinical strains of Staphylococcus aureus

Future Medicinal Chemistry

Volumn 4, Issue 12, 2012, Pages 1541-1551

  Dawgul, Malgorzata ^a   Baranska Rybak, Wioletta ^a   Kamysz, Elzbieta ^b   Karafova, Anna ^a   Nowicki, Roman ^a   Kamysz, Wojciech ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; LINEZOLID; LIPOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; SHORT SYNTHETIC LIPOPEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOFILM; CLINICAL ARTICLE; COLONY FORMING UNIT; CROSS RESISTANCE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIDE SYNTHESIS; PLANKTON; PRIORITY JOURNAL; QUORUM SENSING; SKIN INFECTION; SOLID PHASE SYNTHESIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

ANTI-INFECTIVE AGENTS; BIOFILMS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; QUORUM SENSING; SKIN DISEASES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84865529168     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.100     Document Type: Article

References (65)

1. Dawson AL, Dellavalle RP, Elston DM. Infectious skin diseases: a review and needs assessment. Dermatol. Clin. 30, 141-151 (2012).
2. Percival SL, Emanuel CH, Cutting KF, Williams DW. Microbiology of the skin and the role of biofilms in infection. Int. Wound J. 9(1), 14-32 (2011).
3. Stevens DL, Eron LL. Cellulitis and soft-tissue infections. Ann. Intern. Med. 150(1), ITC11 (2009).
4. Elston DM. Cutaneous manifestations of infectious disease. Med. Clin. N. Am. 93, 1283-1290 (2009).
5. Rogers RL, Perkins J. Skin and soft tissue infections. Prim. Care 33, 697-710 (2006). (Pubitemid 44679781)
6. Iwatsuki K, Yamasaki O, Morizane S, Oono T. Staphylococcal cutaneus infections: invasion, evasion and aggregation. J. Dermatol. Sci. 42, 203-214 (2006).
7. Schlievert PM, Strandberg KL, Lin YCH, Peterson ML, Leung DYM. Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J. Allerg. Clin. Immun. 125(1), 39-49 (2010). Provides crucial information concerning Staphylococcus aureus and helps to realize its significance for current dermatology.
8. Nikolaev YUA, Plakunov VK. Biofilm - city of microbes' or an analogue of multicellular organisms? Microbiology 76(2), 125-138 (2007). The analogy between biofilms and multicellular organisms, as well as the reasons for biofilm resistance to antibiotics are discussed in this review.
9. Potera C. Biofilm dispersing agent rejuvenates older antibiotics. Environ. Health Persp. 118(7), a288 (2010).
10. Shapiro JA, Nguyen VL, Chamberlain NR. Evidence for persisters in Staphylococcus epidermidis RP62a planktonic cultures and biofilms. J. Med. Microbiol. 60(Pt 7), 950-960 (2011).
11. Coenye T, Nelis HJ. In vitro and in vivo model systems to study microbial biofilm formation. J. Microb. Methods 83(2), 89-105 (2010).
12. Vergidis P, Patel R. Novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections. Inf. Dis. Clin. N. Am. 26(1), 173-186 (2012).
13. Aslam S, Darouiche RO. Role of antibiofilmantimicrobial agents in controlling devicerelated infections. Int. J. Art. Org. 34(9), 752-758 (2011).
14. Berra L. Internally coated endotracheal tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: a clinical trial. Int. Care Med. 34(6), 1030-1037 (2008). (Pubitemid 351903803)
15. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell. Microbiol. 11(7), 1034-1043 (2009).
16. Lynch AS, Robertson GT. Bacterial and fungal biofilm infections. Ann. Rev. Med. 59, 415-428 (2008). (Pubitemid 351287946)
17. Hell E, Giske CG, Nelson A, Römling U, Marchini G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett. Appl. Microbiol. 50, 211-215 (2010).
18. Bruellhoff K, Fiedler J, Möller M, Groll J, Brenner RE. Surface coating strategies to prevent biofilm formation on implant surfaces. Int. J. Art. Org. 33(9), 646-653 (2010).
19. Costa F, Carvalho IF, Montelaro RC, Gomes P, Martins MCL. Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater. 7(4), 1431-1440 (2011).
20. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76, 4176-4182 (2008).
21. Shank EA, Kolter R. Extracellular signaling and multicellularity in Bacillus subtilis. Curr. Opin. Microbiol. 14(6), 741-747 (2011).
22. Belley A, Neesham-Grenon E, McKay G et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53, 918-925 (2009).
23. Schauber J, Gallo RL. Antimicrobial peptides and skin immune defense system. J. Allergy Clin. Immunol. 124, 13-18 (2009). Interesting article summarizing the role of antimicrobial peptides (AMPs) in the innate immune system.
24. Yoshinari M, Kato T, Matsuzaka K, Hayakawa T, Shiba K. Prevention of biofilm formation on titanium surfaces modified with conjugated molecules comprised of antimicrobial and titanium-binding peptides. Biofouling 26, 103-110 (2010).
25. Willcox MD, Hume EB, Aliwarga Y, Kumar N, Cole N. A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. J. Appl. Microbiol. 105, 1817-1825 (2008).
26. Cirioni O, Giacometti A, Ghiselli R et al. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 27, 1210-1216 (2006). (Pubitemid 43767009)
27. Lobos O, Padilla A, Padilla C. In vitro antimicrobial effect of bacteriocin PsVP-10 in combination with chlorhexidine and triclosan against Streptococcus mutans and Streptococcus sobrinus strains. Arch. Oral Biol. 54, 230-234 (2009).
28. Arslan SY, Leung KP, Wu CD. The effect of lactoferrin on oral bacterial attachment. Oral Microbiol. Immunol. 24, 411-416 (2009).
29. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22(12), 2329-2343 (2001).
30. Eckert R. Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microb. 66(4), 859-862 (2011). Presents potential strategies aiming to increase of the stability, reduce the cytotoxicity or improve the antimicrobial activity of AMPs.
31. Kamysz W, Silvestri C, Cirioni O et al. In vitro activities of the lipopeptides Palmitoyl (Pal)-Lys-Lys-NH2 and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant Gram-positive cocci. Antimicrob. Agents Chemother. 51(1), 354-358 (2007). Determined the reason to consider lipopeptides as potential antistaphylococcal agents. (Pubitemid 46047729)
32. Cirioni O, Giacometti A, Ghiselli R et al. The lipopeptides Pal-Lys-Lys-NH2 and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection. Peptides 28(6), 1299-1303 (2007). Results of above mentioned study have encouraged authors to test a larger group of lipopeptides according to their potential antibiofilm activity. (Pubitemid 46843383)
33. Makovitzki A, Avrahami D, Shai Y. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl Acad. Sci. USA 103, 15997-16002 (2006). Presents the potential of short lipopeptides towards a broad spectrum of microorganisms. (Pubitemid 44657581)
34. Makovitzki A, Viterbo A, Brotman Y, Chet I, Shai Y. Inhibition of fungal and bacterial plant pathogens in vitro and in planta with ultrashort cationic lipopeptides. Appl. Environ. Microbiol. 73, 6629-6636 (2007). (Pubitemid 47623723)
35. Vallon-Eberhard A, Makovitzki A, Beauvais A, Latgé JP, Jung S, Shai Y. Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-Lys-Ala-dAla-Lys. Antimicrob. Agents Chemother. 52(9), 3118-3126 (2008).
36. Barchiesi F et al. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH2 alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. Peptides 28(8), 1509-1513 (2007). (Pubitemid 47247967)
37. Simonetti O, Arzeni D, Ganzetti G et al. In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. Br. J. Dermatol. 161(2), 249-252 (2009).
38. Barchiesi F, Silvestri C, Arzeni D et al. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. Med. Mycol. 47(3), 321-326 (2009).
39. Cirioni O. Lipopeptide laur-CKK-NH2 dimer preserves daptomycin susceptibility and enhances its activity against Enterococcus faecalis. J. Antimicrob. Chemother. 66(4), 859-862 (2011).
40. Pantosti A, Sanchini A, Monaco M. Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol. 2(3), 232-334 (2007).
41. Shore AC, Deasy EC, Slickers P et al. Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55(8), 3765-3773 (2011).
42. Gherardi G, De Florio L, Lorino J, Fico L, Dicuonzo G. Macrolide resistance genotypes and phenotypesamong erythromycin-resistant clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci. FEMS Immunol. Med. Microbiol. 55, 62-67 (2009).
43. Mallick SK, Basak S, Bose S. Inducible clindamycin resistance in Staphylococcus aureus - a therapeutic challenge J. Clin. Diag. Res. 3, 1513-1518 (2009).
44. Stevens DL. Treatments for skin and soft-tissue infections due to MDR Grampositive bacteria. J. Inf. 59(1), 32-39 (2009).
45. Siibak T, Peil L, Xiong L, Mankin A, Remme J, Tenson T. Erythromycin-and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition. Antimicrob. Agents Chemother. 53(2), 563-571 (2009).
46. McNeil JCH, Hulten KG, Kaplan SL, Mason EO. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrob. Agents Chemother. 55(5), 2431-2433 (2011).
47. Moody MN, Morrison LK, Tyring SK. Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Ther. Lett. 15(1), 1 (2010).
48. Farrell DJ, Robbins M, Rhys-Williams W, Love WG. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob. Agents Chemother. 55(3), 1177-1181 (2011).
49. Wertheim HF, Verveer J, Boelens HA et al. Effect of mupirocin treatment on nasal, pharyngeal, and perineal carriage of Staphylococcus aureus in healthy adults. Antimicrob. Agents Chemother. 49(4), 1465-1467 (2005). (Pubitemid 40463377)
50. Howden BP, Grayson ML. Dumb and dumber - the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 42, 394-400 (2006). (Pubitemid 43122319)
51. Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007-2008. Antimicrob. Agents Chemother. 54(9), 3614-3617 (2010).
52. Gould JM, Canda R, Esposito S, Gudid F, Harbarth S. Management of serious methicillin-resistant Staphylococcus aureus (MRSA) infections: what are the limits? Int. J. Antimicrob. Agents 37, 202-209 (2011).
53. Gould JM, David MZ, Esposito S et al. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. Antimicrob. Agents 39, 96-104 (2012).
54. Giacometti A, Cirioni O, Kamysz W et al. In vitro activity and killing effect of uperin 3.6 against Gram-positive cocci isolated from immunocompromised patients. Antimicrob. Agents Chemother. 49(9), 3933-3936 (2005). (Pubitemid 41233053)
55. Giacometti A, Cirioni O, Riva A et al. In vitro activity of aurein 1.2 alone and in combination with antibiotics against Gram-positive nosocomial cocci. Antimicrob. Agents Chemother. 51(4), 1494-1496 (2007). (Pubitemid 46586835)
56. Giacometti A, Cirioni O, Kamysz W et al. In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrob. Agents Chemother. 49(3), 1249-1252 (2005). (Pubitemid 40327763)
57. Giacometti A, Cirioni O, Kamysz W et al. In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. Int. J. Antimicrob. Agents 26(3), 235-240 (2005). (Pubitemid 41219610)
58. Rieg S. Susceptibility of clinical Staphylococcus aureus isolates to innate defense antimicrobial peptides. Microb. Inf. 13(8-9), 761-765 (2011).
59. Sigurdardottir T, Andersson P, Davoudi M, Malmsten M, Schmidtchen A, Bodelsson M. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrob. Agents Chemother. 50(9), 2983-2989 (2006). (Pubitemid 44396402)
60. Baranska-Rybak W, Dawgul M, Bielinska S, Kraska B, Piechowicz L, Kamysz W. Colorimetric evaluation of the time-killing assay for Citropin 1.1, lipopeptide Palm-KK-NH2, and Temporin A. J. Microbiol. Biotechnol. 21(5), 536-539 (2011).
61. Bowdish DME, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77, 451-459 (2005). (Pubitemid 40489520)
62. Minardi D, Ghiselli R, Cirioni O et al. The antimicrobial peptide Tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model. Peptides 28(12), 2293-2298 (2007). (Pubitemid 350116312)
63. Ghiselli R, Giacometti A, Cirioni O et al. Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. JPEN J. Parenter. Enteral Nutr. 31(6), 463-468 (2007). (Pubitemid 350045484)
64. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr. Top Microbiol. Immunol. 322, 107-132 (2008).
65. Lewis K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5, 48-56 (2006).